

# Takeda Research & Development Fact Sheet

At Takeda, we are a forward-looking, world-class R&D organization that unlocks innovation and delivers transformative therapies to patients. By focusing R&D efforts on four therapeutic areas and other targeted investments, we push the boundaries of what is possible in order to bring life-changing therapies to patients worldwide.

## Our Focus Areas



### ONCOLOGY

We endeavor to deliver novel medicines to patients with cancer worldwide through our three strategic pillars: hematologic malignancies, lung cancer and immunology (I/O).

**11**

clinical-stage assets



### GASTROENTEROLOGY (GI)

We work to restore Life to Living for patients suffering with GI diseases across our core disease areas: inflammatory bowel disease, celiac and other luminal gut diseases, motility disorders and liver diseases.

**9**

clinical-stage assets



### RARE DISEASES

We aspire to transform the treatment of rare immunology, rare hematology and lysosomal storage disorders and expand our focus to bring transformative or curative therapies to other rare diseases.

**7**

clinical-stage assets



### NEUROSCIENCE

Our mission is to bring innovative medicines to patients suffering from neurologic and psychiatric diseases for whom there are no treatments available.

**9**

clinical-stage assets

## A Diverse & Dynamic Pipeline<sup>1</sup>



**40**


NEW MOLECULAR ENTITY  
CLINICAL STAGE ASSETS<sup>2</sup>



PIPELINE WITH ORPHAN  
DRUG DESIGNATION

### MODALITY-DIVERSE RESEARCH PROJECTS

Our Research engine is investing in next-generation technologies beyond small molecules to bring a new wave of innovative treatments to patients.



### PUTTING PATIENTS FIRST

Takeda's R&D patient access programs, knowledge sharing and capacity building programs have been recognized as **Industry Best Practices** by the Access to Medicine Foundation.

### R&D ESTABLISHED:

**20+** PARTNERSHIPS    **50+** INITIATIVES

with non-governmental organizations since 2015 to support local R&D and healthcare capacity building in underserved countries and communities.

### EXTERNALLY ORIENTED MINDSET

We seek innovation and partner to nurture it, wherever it resides. We have diverse partnership models, each created with aligned incentives and designed to leverage what we each do best - together.

Since FY16

**200+** Active Partnerships

**45+** Venture Investment Financings

**25+** New Company Creations

<sup>1</sup> Pipeline as of May 14, 2019

<sup>2</sup> Includes assets in our four focus Therapeutic Areas and targeted R&D investments in Plasma-Derived Therapies and Vaccines  
© Takeda Pharmaceutical Company Limited. All rights reserved. July 2019.




## Our Global Footprint



**SAN DIEGO, CA**  
GI, Neuroscience,  
Discovery Technologies

**BOSTON, MA**  
R&D Center, Oncology,  
GI, Rare Diseases

**SHONAN, JAPAN**  
Neuroscience,  
Takeda & the  
Center for iPS  
Cell Research &  
Application, iPark



Employees Worldwide

**4,400+**

## Regional Centers\*

**OSAKA, JAPAN**  
**TOKYO, JAPAN**

**SHANGHAI, CHINA**  
**SINGAPORE**

**ZÜRICH, SWITZERLAND**  
**VIENNA & ORTH, AUSTRIA**

*\*Each regional center also has a secondary support team in the general vicinity to support local regulatory engagement and sustain other R&D activities.*

### LOCAL SITES

Takeda operates in additional countries for specific R&D functions and/or based on legal requirements.

## R&D Leadership Team



**Andy Plump**  
President, Research  
& Development



**Asit Parikh**  
Head,  
Gastroenterology  
Therapeutic Area Unit



**Emiliangelo Ratti**  
Head, Neuroscience  
Therapeutic Area  
Unit



**Phil Rowlands**  
Head, Oncology  
Therapeutic Area  
Unit



**Dan Curran**  
Head, Rare Diseases  
Therapeutic Area Unit



**Steve Hitchcock**  
Head, Research



**Nenad Grmusa**  
Head, Center for  
External Innovation



**Georgia Keresty**  
R&D Chief  
Operating Officer



**Wolfram Nothaft**  
Chief Medical  
Officer



**Wolfgang Hackel**  
Head, Global R&D  
Finance



**Jeremy Chadwick**  
Head, Regulatory,  
GPSE, Development  
Operations & Clinical  
Supply Chain



**Anne  
Heatherington**  
Head, Data Sciences  
Institute



**Stefan Wildt**  
Head, Pharmaceutical  
Sciences & Translational  
Engine, Cell Therapies



**Erika Marder**  
Head, Global R&D  
Human Resources



**Colleen  
Beauregard**  
Head, Global R&D  
Communications



**Toshio Fujimoto**  
General Manager,  
Shonan Health  
Innovation Park (iPark)